Evidence map›Paper›PMID 28355355›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2017

CIRBP protects H9C2 cells against myocardial ischemia through inhibition of NF-κB pathway.

T Y Long, R Jing, F Kuang, L Huang, Z X Qian, T L Yang

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. CLEC3B protects H9c2 cardiomyocytes from apoptosis caused by hypoxia via the PI3K/Akt pathway.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

T Y LongCardiovascular Department, The Xiangya Hospital of Central South University, Changsha City, Hunan Province, China.
R JingCardiovascular Department, The Xiangya Hospital of Central South University, Changsha City, Hunan Province, China.
F KuangDepartment of Cardiac Surgery, The First Affiliated Hospital of Xiamen University, Xiamen City, Fujian Province, China.
L HuangDepartment of Cardiac Surgery, Shenzhen Hospital of Peking University, Shenzhen City, Guangdong Province, China.
Z X QianDepartment of Emergency, The Xiangya Hospital of Central South University, Changsha City, Hunan Province, China.
T L YangCardiovascular Department, The Xiangya Hospital of Central South University, Changsha City, Hunan Province, China.
Xiangya Hospital Central South University · CNCentral South University · CNFirst Affiliated Hospital of Xiamen University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial ischemia is a major cause of death and remains a disease with extremely deficient clinical therapies and a major problem worldwide. Cold inducible RNA-binding protein (CIRBP) is reported to be involved in multiple pathological processes, including myocardial ischemia. However, the molecular mechanisms of myocardial ischemia remain elusive. Here, we first overexpressed CIRBP by transfection of pc-CIRBP (pcDNA3.1 containing coding sequenced for CIRBP) and silenced CIRBP by transfection of small interfering RNA targeting CIRBP (siCIRBP). pcDNA3.1 and the negative control of siCIRBP (siNC) were transfected into H9C2 cells to act as controls. We then constructed a cell model of myocardial ischemia through culturing cells in serum-free medium with hypoxia in H9C2 cells. Subsequently, AlamarBlue assay, flow cytometry and western blot analysis were used, respectively, to assess cell viability, reactive oxygen species (ROS) level and apoptosis, and expression levels of IκBα, p65 and Bcl-3. We demonstrated that CIRBP overexpression promoted cell proliferation (P<0.001), inhibited cell apoptosis (P<0.05), reduced ROS level (P<0.001), down-regulated phosphorylated levels of IκBα and p65 (P<0.01 or P<0.001), and up-regulated expression of Bcl-3 (P<0.001) in H9C2 cells with myocardial ischemia. The influence of CIRBP knockdown yielded opposite results. Our study revealed that CIRBP could protect H9C2 cells against myocardial ischemia through inhibition of NF-κB pathway.

Indexed as

AnimalsApoptosisBlotting, WesternCell ProliferationCells, CulturedCell SurvivalFlow CytometryGene Expression RegulationMyocardial IschemiaNF-kappa BProtective AgentsRatsReactive Oxygen SpeciesReproducibility of ResultsReverse Transcriptase Polymerase Chain ReactionRNA-Binding ProteinsCIRBP protein, humanNF-kappa BProtective AgentsReactive Oxygen SpeciesRNA-Binding ProteinsRNA, Small Interfering

Identifiers

PMID28355355
PMCPMC5423751
OpenAlexW2599923384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.